Free Trial
NASDAQ:KTTA

Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

Pasithea Therapeutics logo
$0.52 +0.00 (+0.40%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.49 -0.04 (-6.70%)
As of 11/13/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Pasithea Therapeutics Stock (NASDAQ:KTTA)

Advanced

Key Stats

Today's Range
$0.46
▼
$0.58
50-Day Range
$0.37
▼
$0.60
52-Week Range
$0.28
▼
$2.06
Volume
2.36 million shs
Average Volume
1.59 million shs
Market Capitalization
$17.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Hold

Company Overview

Pasithea Therapeutics is a clinical-stage biotechnology company developing therapies for serious diseases. Its current focus is PAS-004, a next-generation macrocyclic MEK inhibitor being studied for conditions associated with the RAS/MAPK signaling pathway, including neurofibromatosis type 1.

The company’s research has shifted over time: Pasithea previously focused on treatments for neurological and psychiatric disorders. Its current development efforts are centered on PAS-004 and potential applications in diseases with limited treatment options.

Pasithea is headquartered in the United States and is listed on the Nasdaq under the ticker KTTA.

AI Generated. May Contain Errors.

Pasithea Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

KTTA MarketRank™: 
2.858642866515 of 5 stars

Pasithea Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 432nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pasithea Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Pasithea Therapeutics has a consensus price target of $3.00, representing about 474.7% upside from its current price of $0.52.

  • Amount of Analyst Coverage

    Pasithea Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Pasithea Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Pasithea Therapeutics are expected to grow in the coming year, from ($0.76) to ($0.46) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pasithea Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pasithea Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pasithea Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.17% of the float of Pasithea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pasithea Therapeutics has a short interest ratio ("days to cover") of 0.84, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pasithea Therapeutics has recently increased by 121.49%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pasithea Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Pasithea Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Pasithea Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Pasithea Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    2 people have added Pasithea Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.50% of the stock of Pasithea Therapeutics is held by insiders.

  • Percentage Held by Institutions

    23.92% of the stock of Pasithea Therapeutics is held by institutions.

  • Read more about Pasithea Therapeutics' insider trading history.
Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KTTA Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Headlines

KTTA Stock Analysis - Frequently Asked Questions

Pasithea Therapeutics' stock was trading at $1.29 at the start of the year. Since then, KTTA shares have decreased by 59.5% and is now trading at $0.5220.

Pasithea Therapeutics Corp. (NASDAQ:KTTA) posted its quarterly earnings data on Friday, November, 13th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01.

Shares of Pasithea Therapeutics reverse split on Tuesday, January 2nd 2024.The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Pasithea Therapeutics (KTTA) raised $17 million in an initial public offering on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Plug Power (PLUG), Advanced Micro Devices (AMD), Can-Fite BioPharma (CANF) and Ginkgo Bioworks (DNA).

Company Calendar

Last Earnings
11/13/2026
Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:KTTA
CIK
1841330
Fax
N/A
Employees
5
Year Founded
2020

Price Target and Rating

High Price Target
$3.00
Low Price Target
$3.00
Potential Upside/Downside
+474.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.43 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.49%
Return on Assets
-46.81%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
26.25
Quick Ratio
26.25

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.39 per share
Price / Book
0.22

Miscellaneous

Outstanding Shares
33,410,000
Free Float
32,913,000
Market Cap
$17.44 million
Optionable
Not Optionable
Beta
0.39

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:KTTA) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners